781-93-1

Upstream product

• 100-63-0 phenylhydrazine 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 
• 59-88-1 phenylhydrazine hydrochloride 

Downstream Products

• 723-74-0 1-methyl-2-phenyl-5-trifluoromethyl-1,2-dihydro-3H-pyrazol-3-one 
• 2730-02-1 1,5-diphenyl-3-(trifluoromethyl)-1H-pyrazole 
• 1067647-63-5 α-hydroxy-2,5-dihydro-5-oxo-1-phenyl-α-trifluoromethyl-3-trifluoromethyl-1H-pyrazole-4-acetic acid methyl ester 
• 1257412-09-1 C₂₅H₁₈F₄N₂O₃ 
• 956708-40-0 C₂₆H₁₇F₃N₄O 

Relevant academic research and scientific papers

Efficient Synthesis of Five Types of Heterocyclic Compounds via Intramolecular Elimination Using Ultrasound-Static Heating Technique

An experimental technique, ultrasound-static heating, has been developed for the efficient synthesis of heterocyclic compounds. The technique involves ultrasonic irradiation and static heating processes. First, the ultrasonic irradiation process is performed to form an intermediate of the heterocyclic compound under mild conditions and the subsequent static heating process (heating the intermediate under solvent-free conditions without stirring) produces the target heterocyclic compounds via intramolecular elimination.

Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold

HIV-1 integrase (IN), one of the essential enzymes in HIV infection, has been validated as a target for HIV treatment. While more than 20 drugs have been approved by the FDA to treat HIV/AIDS, only one drug, Raltegravir (1), was approved as an IN inhibitor. The rapid mutation of the virus, which leads to multidrug resistant HIV strains, presents an urgent need to find potent compounds that can serve as second-generation IN inhibitors. The pyrazolone scaffold, predicted by a computational modeling study using GS-9137(2) as a pharmacophoric model, has shown to inhibit the IN catalytic activities in low micromolar range. We have synthesized various analogs based on the pyrazolone scaffold and performed SAR studies. This paper will showcase the up-to-date result of this scaffold as a promising HIV-1 IN inhibitor.